Pretreatment of therapeutic cells with poly(ADP-ribose) polymerase inhibitor enhances their efficacy in an in vitro model of cell-based therapy in myocardial infarct

Author：          

Publisher： Spandidos Publications

ISSN： 1107-3756

Source： International Journal of Molecular Medicine, Vol.31, Iss.1, 2013-01, pp. : 26-32

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

3‐aminobenzamide, a poly (ADP ribose) polymerase inhibitor, enhances wound healing in whole body gamma irradiated model

By  

WOUND REPAIR AND REGENERATION, Vol. 23, Iss. 5, 2015-09 ,pp. : 672-684

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Trials of Poly(ADP-Ribose) Polymerase Inhibitors for Cancer Therapy: A Review

By  

Reviews on Recent Clinical Trials, Vol. 10, Iss. 4, 2015-12 ,pp. : 326-339

Bentham Science Publishers

Access to resources Recommend Favorite

The world according to poly(ADP-ribose) polymerase (PARP)—update 2006

By Barth Eberhard   Radermacher Peter   Szabó Csaba  

Intensive Care Medicine, Vol. 32, Iss. 10, 2006-10 ,pp. : 1470-1474

Springer Publishing Company

Access to resources Recommend Favorite

Autoantibodies to Poly(ADP-Ribose) Polymerase in Centenarians: A Reappraisal of Grabar’s Hypothesis

By  

Gerontology, Vol. 55, Iss. 4, 2009-04 ,pp. : 427-429

Karger

Access to resources Recommend Favorite

Synergistic cytotoxicity of the poly (ADP‐ribose) polymerase inhibitor ABT‐888 and temozolomide in dual‐drug targeted magnetic nanoparticles

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 4, 2015-04 ,pp. : 1430-1441

John Wiley & Sons Inc

Access to resources Recommend Favorite